Search for: "Myriad Genetic Laboratories" Results 1 - 20 of 155
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Oct 2023, 8:17 am by LaBovick Law Group
The severity and progression of osteoarthritis are influenced by several factors including age, weight, genetics, and previous injuries. [read post]
12 Jan 2023, 7:00 am by Jason Rantanen
Rather, this function is usually carried out by public health agencies and academic laboratories, typically in the locale of the outbreak, and which are supported by public funds. [read post]
23 Nov 2022, 6:14 am by Kirk M. Hartung
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. [read post]
22 Aug 2022, 9:15 am by Eileen McDermott
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. [read post]
22 Aug 2022, 9:15 am by Eileen McDermott
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. [read post]
3 Aug 2022, 7:02 am by Gene Quinn
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. [read post]
3 Aug 2022, 7:02 am by Gene Quinn
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. [read post]
21 Apr 2020, 5:45 am by Guest Author for TradeSecretsLaw.com
Myriad Genetics (“Myriad”);[2] and Alice Corporation Pty Ltd. v. [read post]
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
CLIA imposes a wide range of requirements on laboratories, ranging from the laboratory level (including the physical facilities available and the credentials of the laboratory employees) to the level of each diagnostic test (requiring each type of test run by a laboratory to meet substantive proficiency testing standards). [read post]
2 Oct 2019, 10:00 pm
Myriad Genetics, Inc,  as proclaiming that “groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry. [read post]
14 Jan 2019, 2:40 am by Camilla Alexandra Hrdy
Meanwhile, the studies ignore, presumably because they cannot realistically measure, indirect costs like "loss of health (or life) that may have resulted from" "the higher financial costs to patients" of life-saving drugs and diagnostic tests, such as Myriad Genetics' breast and ovarian cancer tests. (12-14).In the end, Biagioli appears, like Fritz Machlup, to be unimpressed. (14) ("Returning to the key question of what these studies tell us, the short… [read post]